Part 2: Best Practices in Managing Early Breast Cancer With a High Risk of Recurrence
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
Part 2: Best Practices in Managing Early Breast Cancer With a High Risk of Recurrence
-
Gesprochen von:
-
Von:
Über diesen Titel
We are pleased to present Part 2 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.
Part 2 of this series provides peer-to-peer physician perspectives on best practices in managing early breast cancer.
Topics include:
- Best practices in treating early HR-positive/HER2-negative breast cancer with a high risk of recurrence
- Balancing efficacy and quality of life during maintenance endocrine therapy with adjuvant CDK4/6 inhibitor treatment
Discussants:
Neil M. Iyengar, MD
Director, Survivorship Services, Winship Cancer Institute of Emory University
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA
Seth Wander, MD, PhD
Director, Precision Medicine, Termeer Center for Targeted Therapies
Director, Translational Research, Breast Oncology Program
Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA
Sponsored by Lilly
